Background-We sought to determine whether empirical nesiritide or milrinone would improve the early postoperative course after Fontan surgery. We hypothesized that compared with milrinone or placebo, patients assigned to receive nesiritide would have improved early postoperative outcomes. Methods and Results-In a single-center, randomized, double-blinded, placebo-controlled, multi-arm parallel-group clinical trial, patients undergoing primary Fontan surgery were assigned to receive nesiritide, milrinone, or placebo. A loading dose of study drug was administered on cardiopulmonary bypass followed by a continuous infusion for ≥12 hours and ≤5 days after cardiac intensive care unit admission. The primary outcome was days alive and out of the hospital within 30 days of surgery. Secondary outcomes included measures of cardiovascular function, renal function, resource use, and adverse events. Among 106 enrolled subjects, 35, 36, and 35 were randomized to the nesiritide, milrinone, and placebo groups, respectively, and all were analyzed based on intention to treat. Demographics, patient characteristics, and operative factors were similar among treatment groups. No significant treatment group differences were found for median days alive and out of the hospital within 30 days of surgery (nesiritide, 20 [minimum to maximum, 0-24]; milrinone, 18 [0-23]; placebo, 20 [0-23]; P=0.38). Treatment groups did not significantly differ in cardiac index, arrhythmias, peak lactate, inotropic scores, urine output, duration of mechanical ventilation, intensive care or chest tube drainage, or adverse events. Conclusions-Compared with placebo, empirical perioperative nesiritide or milrinone infusions are not associated with improved early clinical outcomes after Fontan surgery. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00543309. (Circ Heart Fail. 2014;7:596-604.)
T he staged surgical pathway to treat children with a functional single-ventricle heart defect culminates with the Fontan operation, during which all systemic venous return is routed directly to the pulmonary arteries, thus separating the systemic and pulmonary circulations. Because there is no pulmonary ventricle, pulmonary blood flow and preload to the systemic ventricle are critically dependent on the transpulmonary pressure gradient. Systemic vasodilation is often used after the Fontan operation, both to reduce afterload on the systemic ventricle and to augment pulmonary blood flow. Although mortality after the Fontan operation is now uncommon, early postoperative morbidity can be significant. A low cardiac output state characterized by elevated Fontan baffle and cardiac filling pressures and systemic and pulmonary vascular resistance may develop, contributing to prolonged postoperative chest tube drainage and hospitalization. Treatment strategies that augment systemic and pulmonary blood flow and mitigate potential complications are desirable.
Clinical Perspective on p 604
Natriuretic hormones decrease vascular resistance, attenuate the renin-angiotensin-aldosterone axis, suppress vasopressin and catecholamine release, and promote natriuresis and diuresis. 1 Natriuretic hormones also have lusitropic properties and limit myocardial ischemia-reperfusion injury. 2, 3 Nesiritide, a recombinant human B-type natriuretic peptide, has favorable effects on patient symptoms, hemodynamics, and the neurohumoral profile in adults with decompensated congestive heart failure and in those recovering from cardiac surgery involving cardiopulmonary bypass (CPB). 4, 5 Milrinone, an inodilator with lusitropic properties, has been shown to decrease the incidence of low cardiac output syndrome after cardiac surgery in children with 2-ventricle heart defects. 6 In children undergoing the Fontan procedure, milrinone is often used in the perioperative period in many centers. The properties of nesiritide and milrinone are intuitively of potential benefit in single-ventricle patients, yet no published data have evaluated their safety and efficacy after Fontan surgery.
The purpose of this study was to determine whether perioperative infusions of nesiritide or milrinone compared with placebo would have beneficial effects on the early postoperative clinical course and neurohormonal profile of children undergoing Fontan surgery.
Methods

Study Design, Setting, and Oversight
This randomized, double-blinded, placebo-controlled, multi-arm parallel-group phase II clinical trial was conducted in the cardiac operating rooms and cardiac intensive care unit (CICU) in a single center from October 2007 to January 2013. The anesthetic and surgical techniques used for primary Fontan completion at our institution during this trial were fairly standardized. The type of Fontan surgery (eg, lateral tunnel, extracardiac conduit), as well as methods of vital organ support and anesthesia, was performed according to routine clinical practice. The institutional strategy typically included routine use of an aortic cross-clamp with cardioplegic arrest and standardized hematocrit and pH management during CPB. Ultrafiltration was routinely used during rewarming from CPB, but modified ultrafiltration was not used.
The study was approved by the institutional review board, and written informed consent was obtained from the parents or guardians of all participating subjects. The trial was registered at ClinicalTrials. gov (unique identifier 0735070N). An investigational new drug application (77358) was issued for nesiritide by the Food and Drug Administration of the Department of Health and Human Services.
Study Patients
Eligible participants were all patients undergoing a primary Fontan operation. Exclusion criteria were a preoperative serum creatinine >1.5 mg/dL, chronic dialysis, revision surgery for failing Fontan circulation, or a request by the attending cardiac surgeon or cardiologist not to approach the patient for enrollment. Eligible participants were recruited by mailing information about the study to the patient's home several weeks before surgery and by in-person meetings with study investigators during the pre-Fontan cardiac catheterization or at the preoperative clinic visit.
Study Drug Administration
Patients were randomly assigned to receive milrinone (Baxter Healthcare Corporation, Deerfield, IL), nesiritide (Natrecor, Scios Inc, Fremont, CA), or placebo. The block randomization sequence was determined by computer-generated numbers in a 1:1:1 allocation using block sizes of 6, stratified by whether there was a preoperative plan for additional cardiac surgical procedures at the time of Fontan operation (eg, valvuloplasty, aortic arch reconstruction). Allocation concealment was achieved using sequentially numbered opaque, sealed envelopes that were kept in a locked central pharmacy and opened by a pharmacist on the morning of surgery. Patients, investigators, and treating clinicians were blinded to treatment assignment.
The study drug was initiated in the operating room before the onset of rewarming from CPB (and before removal of the aortic cross-clamp, when applicable). Using indistinguishable syringes and identical volumes of administered study drug, patients assigned to the nesiritide group received an intravenous loading dose of 2 μg/kg followed by an infusion of 0.015 μg/kg per minute. This dosing regimen was based on retrospective case series in children [7] [8] [9] and prospective adult trials. 10 Patients assigned to the milrinone group received an intravenous bolus of 50 μg/kg followed by an infusion of 0.5 μg/kg per minute. This dosing regimen is within the range found to be efficacious in a prior multicenter study of empirical milrinone use after complex 2-ventricular repairs in children. 6 Those assigned to the placebo group received a 0.33 mL/kg bolus of 5% dextrose in water, followed by an infusion of 5% dextrose in water. In the event of hypotension or at the discretion of the attending physicians, the protocol allowed for study drug initiation to be delayed until the patient was separated from CPB or admitted to the CICU. At the discretion of the attending physicians or in the event of hypotension (defined by a systolic blood pressure <75 mm Hg despite administration of volume and a dopamine infusion), the protocol also allowed for the study drug infusion rate to be halved or transiently held. Similarly, if the attending physician thought that the patient could benefit from more vasodilator therapy, the infusion rate could be doubled, yielding maximal doses of nesiritide of 0.03 μg/kg per minute and milrinone of 1.0 μg/kg per minute. Per protocol, the study drug was discontinued in the CICU when ≥12 hours of study drug infusion had been administered and the study drug was no longer thought to be clinically indicated by the attending cardiac intensivist or surgeon or when 120 hours of study drug infusion was reached, whichever came first. The protocol also specified that the study drug would be discontinued for lack of efficacy when ≥1 of the following events occurred: elevated filling pressures (defined as a central venous pressure >22 mm Hg, transpulmonary gradient >14 mm Hg, or common atrial pressure >14 mm Hg for 2 hours despite routine medical management); elevated serum lactate levels (defined as a lactate >10 mmol/L and rising by >3 mmol/L on 2 serial measurements or lactate rising by >3 mmol/L on each of the 3 serial measurements); persistent hypotension (defined by a systolic blood pressure <75 mm Hg for >30 minutes that was refractory to volume administration, increased inotropic/vasopressor support, and weaning of other vasodilators); acute renal insufficiency (defined as a >3-fold increase in serum creatinine compared with the preoperative value or need for dialysis); cardiopulmonary resuscitation, definite plan for Fontan takedown or other cardiac reoperation, or requirement for mechanical cardiac support. The study drug could also be discontinued if the attending cardiac intensivist or surgeon had a compelling indication for stopping the study drug that did not meet the above criteria or if a parent or guardian withdrew consent. Once the study drug was stopped based on 1 of these 4 criteria, the managing clinicians were allowed to prescribe open-label milrinone or nesiritide at their discretion. The postoperative management in the CICU was otherwise conducted according to routine clinical practice.
End Points
The primary outcome was the number of days alive and out of the hospital within 30 days of surgery. Secondary outcomes included cardiovascular, renal, resource use, and neurohormonal variables. Cardiac index was measured using the Fick principle with measured oxygen consumption (Vmax Encore, Viasys, Yorba Linda, CA) at 1 and 8 hours of CICU admission. Peak serum lactate concentration and peak inotropic score [dose of dopamine+dose of dobutamine+(dose of epinephrine×100)] 11 and serial measures of CVP were assessed during the first 24 hours of CICU admission. The incidence of arrhythmias (defined as an arrhythmia lasting >30 seconds or requiring treatment during the first 5 days after surgery) and net fluid balance were assessed during the first 5 days after surgery. Measures of renal function included urine output and diuretic requirements during the first 5 days after surgery and maximal change in serum creatinine within 14 days of surgery. Markers of resource use included hours of mechanical ventilation, days of CICU stay and chest tube drainage, and the number of days alive and out of the hospital within 180 days of surgery. In the first 47 study patients, plasma catecholamines and N-terminal pro brain-type natriuretic peptide (NT-pro BNP) levels were measured at baseline and during the first 24 hours after surgery. Insufficient research funds precluded the measurement of these hormones in the remaining study patients. Because natriuretic hormones have been reported to suppress neurohormonal activation in other patient populations, catecholamine levels were assessed. NT-pro BNP levels were obtained as a surrogate for ventricular wall stress and myocardial ischemia-reperfusion injury. Predefined adverse events were prospectively documented throughout the postoperative hospitalization.
Statistical Analysis
The primary hypothesis was that patients assigned to receive nesiritide would have more days alive and out of the hospital within the first 30 days after surgery compared with those assigned to receive either milrinone or placebo. We also hypothesized that nesiritide would have favorable effects on several measures of postoperative cardiovascular function, renal function, and the neurohormonal profile, as well as the duration of mechanical ventilation, chest tube drainage, and intensive care. Based on data from patients who underwent a primary Fontan operation at our institution during the year preceding the onset of the trial (n=44), the expected mean number of days alive and out of hospital within 30 days of surgery was 18.8 days in the milrinone group and 18.3 days in the placebo group. Using a 1-way ANOVA, assuming a mean number of days alive and out of hospital within 30 days of surgery of 18.8 in the milrinone group, 18.3 in the placebo group, and 22.3 in the nesiritide group, an estimated SD of the differences of 5.6 days, a significance of 0.05, and a power of 0.8, the study required 39 patients per treatment group. To recruit this number of patients, a 3.5-year enrollment period was anticipated. The effect size of 3.5 additional days alive and out of the hospital was chosen, given similar or greater impact of other interventions in Fontan patients and based on the effect size seen in a trial of empirical perioperative nesiritide infusions in complex adult cardiac surgery patients. 5, 12, 13 The primary analysis was intention to treat and included all patients who were randomly assigned. Some patients received open-label milrinone once the blinded study drug infusion had been discontinued for lack of efficacy. Thus, for the primary outcome only, an additional outcome variable was created by ranking the number of days alive and out of the hospital within 30 days of surgery for each patient. In this analysis, patients who died were assigned worst rank, and those who met lack of efficacy criteria resulting in discontinuation of the study drug and subsequently received open-label milrinone were assigned the next worse rank. The distribution of ranks among the 3 study groups was compared using the Kruskal-Wallis test.
Given the long duration of the study, patients were divided into 2 groups based on the date of enrollment, and post hoc univariate analyses were conducted on selected patient characteristics and outcomes. The early study era was defined as October 2007 through July 2009 (n=53 patients enrolled) and the later era as August 2009 through January 2013 (n=53 patients enrolled). To examine whether there was a difference in outcome related to preoperative risk, higher risk subjects were defined as those having ≥2 of the following characteristics: right ventricular morphology, ≥moderate ventricular systolic dysfunction or atrioventricular valve regurgitation as assessed by preoperative echocardiogram, preoperative end-diastolic pressure ≥11 mm Hg, pulmonary vascular resistance >2.0 Wood units, or mean pulmonary artery pressure ≥14 mm Hg measured at preoperative cardiac catheterization, or if an additional cardiac procedure was performed during the Fontan admission. Post hoc analyses were conducted comparing the primary and key secondary outcomes in higher risk patients from each treatment group.
An independent data safety and monitoring board periodically reviewed safety and efficacy data. As a result of slow enrollment during the final year of the study, the investigators asked the data safety and monitoring board to approve the conduct of an unplanned interim analysis. On January 16, 2013, the data safety and monitoring board reviewed the results of this analysis and recommended that enrollment in the trial be stopped because of futility.
Data are reported as median (minimum to maximum) or count (%). Preoperative patient characteristics, intraoperative data, and outcomes were compared among the 3 treatment groups using the Kruskal-Wallis test for continuous variables and Fisher exact test for categorical variables. Changes in variables measured at serial time intervals were explored using 2-way ANOVA with repeated measures on one factor. Version 9.3 of the SAS System for Windows (SAS Institute Inc, Cary, NC) was used for statistical analysis.
Results
Study Participants
Of the planned 117 participants, 106 were enrolled between October 2007 and January 2013. There were no significant differences in demographic characteristics or ventricular morphology between the 106 enrolled patients and the 90 patients who were eligible but not enrolled (data not shown). Of the 106 children who were randomized, 35 were assigned to the placebo group, 35 were assigned to the nesiritide group, and 36 were assigned to the milrinone group (Figure 1 ). Baseline characteristics of the treatment groups were similar (Table 1) . Cardiovascular assessment obtained before the Fontan operation, including detailed data obtained by echocardiogram and cardiac catheterization, indicated that the treatment groups were well balanced ( Table 2 ). Intraoperative characteristics of the treatment groups were also similar, except for the use of an aortic cross-clamp, which was most common in the placebo group (Table 3 ). The treatment groups did not differ significantly in intraoperative blood product, crystalloid, cardioplegia, or colloid administration or in urine output, chest tube output, or ultrafiltration volume (data not shown). A fenestration was placed in 95 of 106 (90%) study patients, with no significant differences among treatment groups.
There was a significant difference between study eras in the number of enrolled Fontan patients operated on by each of 7 cardiac surgeons (P<0.001) but no significant overall difference in the type of operation performed (intracardiac lateral tunnel: 75% early era, 70% later era; extracardiac conduit: 23% early era, 24% later era; extracardiac lateral tunnel: 2% early era, 6% later era; P=0.66).
Use of Study Drugs
Study drug administration data are summarized in Table I in the Data Supplement. All but 1 randomized patient received their assigned study drug. This patient who had been assigned to the milrinone group had an intraoperative recurrence of a pre-existing arrhythmia and never received the study drug per attending surgeon's request. There was no significant difference among treatment groups in the reasons for premature discontinuation of study drug infusions (P=0.08). In the majority of cases, the study drug was discontinued in the CICU when no longer thought to be clinically indicated as judged by the attending physicians. Of note, hypotension was the primary reason for stopping the study drug in none of the placebo patients, 14% of nesiritide patients, and 25% of milrinone patients. After study drug discontinuation, open-label milrinone was used in 17%, 29%, and 8% of the placebo, nesiritide, and milrinone patients, respectively. No study patient received open-label nesiritide.
Primary End Point
In the intention-to-treat analysis, the median number of days alive and out of the hospital within 30 days of surgery was 20 days (minimum to maximum, 0-24 days; mean, 17.2 days) in the nesiritide group, 18 days (minimum to maximum, 0-23 days; mean, 16.4 days) in the milrinone group, and 20 days (minimum to maximum, 0-23 days; mean, 18.2 days) in the placebo group (P=0.38; Figure 2 ). In a sensitivity analysis in which the 19 patients whose study drug was stopped for efficacy failure and then received open-label milrinone were assigned the next worst rank after death, there was also no significant difference among treatment groups in the primary outcome (P=0.32).
In a secondary analysis of higher risk subjects, the treatment groups did not differ significantly in the number of days alive and out of the hospital within 30 days of surgery (nesiritide: n=17, median 19 days [minimum to maximum, 0-24 days]; milrinone: n=24, median 18 days [minimum to maximum, 0-23 days]; placebo: n=24, median 20 days [minimum to maximum, 0-23 days]; P=0.87).
Secondary End Points
No significant differences were found among treatment groups for any of the secondary outcomes assessed, including cardiovascular variables, indices of renal function, and resource use ( Table 4 ). There were also no significant differences noted in several other outcomes assessed, including vasopressor or vasodilator use and fluid balance within the first 5 days of surgery, inhaled nitric oxide use, reintubations, unplanned postoperative cardiac procedures, total duration of postoperative hospitalization, or hospital readmissions within 180 days of surgery (data not shown). When only higher risk patients were considered, the treatment groups also did not differ significantly in postoperative cardiac index, days of intensive care, urine output during the first 24 hours after surgery, or adverse events (data not shown).
In the initial 47 study patients enrolled in the trial, epinephrine and norepinephrine plasma levels were measured. Catecholamines levels increased substantially in the early postoperative period, but no significant differences were found among treatment groups (Figure 3 ; Table II in the Data Supplement). NT-pro BNP levels gradually increased during the first 24 hours after CICU admission, with no significant difference found among treatment groups ( Figure I in the Data Supplement).
Era Effect
Compared with patients enrolled in the earlier era of the study, those enrolled in the later era had more days alive and out of the hospital within 30 days of surgery (median of 18 days in earlier era versus 20 days in later era; unadjusted P=0.03) and fewer postoperative CICU days (median 3 days in earlier era versus 2 days in later era; unadjusted P=0.02). However, there were no significant differences between eras in cardiac index, renal function, or adverse events.
Adverse Events
One study patient who was assigned to the nesiritide group died on postoperative day 18. This 15-year-old patient had an extensive preoperative history of atrial arrhythmias that recurred intraoperatively, leading to cardiac arrest and extracorporeal membrane oxygenation cannulation. The patient was ultimately converted to a ventricular assist device but developed sepsis and multiorgan system failure. There were no other hospital deaths and no additional deaths at 180-day follow-up. At least 1 episode of hypotension occurred in 69% of the placebo patients, 69% of the nesiritide patients, and 75% of the milrinone patients (P=0.83). Acute renal insufficiency, defined as a 3-fold increase in creatinine or need for dialysis, occurred in 9% of placebo patients, 6% of nesiritide patients, and 3% of milrinone patients (P=0.53). Adverse event data are summarized in Table III in the Data Supplement.
Discussion
Despite sizeable resource use devoted to the care of patients with single ventricle, no published randomized clinical trials have assessed the optimal postoperative management of the Fontan patient. Based on the unique nature of the Fontan physiology with effective pulmonary blood flow dependent on pulmonary vascular resistance and the transpulmonary gradient, systemic vasodilation is frequently used after the Fontan operation to lower afterload and thereby atrial and ventricular end-diastolic pressures. There may be additional benefits, although untested, related to the lowering of pulmonary vascular resistance and improved diastolic function of the systemic ventricle. However, in this randomized controlled trial we found no outcome advantage of milrinone and nesiritide compared with placebo in children undergoing a primary Fontan operation. No evidence of efficacy for either study drug was found in secondary analyses of higher risk patients. Empirical perioperative milrinone use in Fontan patients continues to be a common practice. Without a pulmonary ventricle, an elevated Fontan baffle pressure in the 10 to 15 mm Hg range and a transpulmonary pressure difference between the Fontan baffle and the atrial pressure (as a surrogate of the systemic ventricle end-diastolic pressure) of 5 to 10 mm Hg are ideal. Therefore, factors after the Fontan surgery that have an adverse impact on preload, pulmonary vascular resistance, and systemic ventricle performance may contribute to prolonged recovery. This prolonged recovery is often manifest as persistent chest tube drainage. In addition to an elevated Fontan baffle pressure, neurohumoral activation during cardiopulmonary bypass induces the release of catecholamines, vasopressin, endothelin, and activation of the renin-angiotensin-aldosterone system. These responses may lead to increased vascular resistance and fluid retention. The use of an aortic cross-clamp with cardioplegic arrest may result in myocardial ischemia-reperfusion injury, leading to systolic and diastolic dysfunction. Because both nesiritide and milrinone have pharmacodynamic properties that have the potential to favorably mitigate many of these disturbances in patients with Fontan physiology, interest in the use of either drug for such patients was justified.
At the onset of this trial, the use of nesiritide in critically ill pediatric cardiac patients was the subject of investigation and speculation, [7] [8] [9] 14 and our findings should be interpreted in light of prior perioperative investigations of these drugs. In a phase II clinical trial in 303 adults with pre-existing heart failure who underwent coronary artery bypass grafting using CPB, patients assigned to receive empirical perioperative nesiritide infusions had significant improvements in urine output, renal function, hospital length of stay, and 6-month mortality. 5 In a pilot study of 8 children recovering from Fontan surgery, a 1-hour atrial natriuretic peptide infusion produced favorable changes in cardiac loading conditions, cardiac index, and urine output. 15 The findings of retrospective case series in children with decompensated heart failure, some of whom were recovering from cardiac surgery, suggest that nesiritide infusions were well tolerated and associated with favorable changes in hemodynamics, fluid balance, renal function, and overall clinical status. 7, 8, 14, 16 The results of our trial stand in contrast to the findings of these pediatric studies, but our study design overcame many of the inherent limitations of retrospective case series. The endogenous biological activity of the natriuretic hormone system may be decreased after CPB in children 17, 18 and specifically after cavopulmonary connection operations. 19 Potential contributing factors include receptor downregulation, alterations in signal transduction, increased phosphodiesterase activity, nonpulsatile flow, and hypothermia. 20, 21 In vitro and in vivo studies have found that natriuretic hormones provide protection from myocardial ischemia-reperfusion injury, likely related to modulation of intracellular calcium levels, pH, and angiotensin II effects, which may benefit patients undergoing cardioplegic arrest. 2, 3, 22 In light of the above data, the rationale to study nesiritide in Fontan patients seemed compelling. The early postoperative Fontan state can be characterized by systolic and diastolic myocardial dysfunction, a propensity for arrhythmias, marked neurohormonal activation, and fluid retention. [23] [24] [25] The administration of a drug that may mitigate myocardial ischemia-reperfusion injury and promote lusitropy and neurohormonal inhibition, as well as systemic and pulmonary vasodilation, seemed attractive. However, our findings indicate that empirical nesiritide use was not beneficial for patients undergoing a Fontan operation.
Milrinone selectively inhibits the phosphodiesterase III isozyme, resulting in cAMP-mediated increases in intracellular ionized calcium and contractile force in cardiac muscle. Milrinone also causes cAMP-dependent contractile protein phosphorylation and relaxation in vascular muscle. Milrinone has inotropic, vasodilatory, and lusitropic effects. Despite the absence of prior safety and efficacy data, milrinone is routinely used by many clinicians after the Fontan operation. In a pilot study involving 8 Fontan patients, a 2-hour bolus of amrinone, another phosphodiesterase III inhibitor, resulted in lower pulmonary and systemic vascular resistance and higher cardiac index, but was associated with hypotension for which study patients were given an average of 14 mL/kg of colloid infusion. 26 In our study, we found that empirical milrinone administration was not associated with improvement in a variety of important, objective clinical outcomes in patients undergoing a Fontan operation. Of note, milrinone was discontinued in one quarter of subjects who received it because of hypotension, and arrhythmias were nearly twice as common in those patients receiving milrinone compared with the placebo group.
Our study highlights a lack of efficacy and potential safety concerns for a treatment that was widely thought to be beneficial. Our findings differ from those reported in the PRIMACORP (PRophylactic Intravenous use of Milrinone After Cardiac OpeRation in Pediatrics) trial, in which milrinone was shown to decrease the incidence of clinical low cardiac output syndrome after cardiac surgery in infants and young children with 2-ventricle heart defects. 6 In addition to the distinctly different patient demographics in the studies, the cardiovascular pathophysiology associated with a 2-ventricular circulation is markedly different than that encountered after a Fontan operation. Furthermore, the physiological effects (if any) of milrinone or nesiritide on the systemic venous vasculature are unknown. In theory, any systemic venous dilation caused by either drug, when combined with positive pressure ventilation, may compromise preload to the functional single ventricle, thereby offsetting any favorable pharmacodynamic drug effects. A better understanding is needed of the pathophysiology of postoperative Fontan patients in general and their interpatient variation and interaction with inodilators.
The study had several limitations. The single-center design limits the generalizability of our findings to other institutions. In particular, the majority of patients received a fenestration as a part of the Fontan operation and a perioperative dopamine infusion, and none were extubated in the operating room. There was no systematic change in our routine perioperative practices during the trial, but we are unable to comment on whether there may have been differences in outcomes with other strategies. Furthermore, marked interpatient variation in plasma catecholamines and NT-pro BNP levels was evident before and early after surgery, suggesting subtle differences between patients in cardiovascular pathophysiology that may not have been evident by routine assessment and monitoring. Thus, although the patient characteristics and intraoperative management were well balanced among treatment groups, the possibility remains that unmeasured confounding variables or practices ultimately lead to similar outcomes among treatment groups. The dosing regimens used for the study drugs were extrapolated from favorable published experience in other patient populations. However, pharmacokinetic and pharmacodynamic data were not available for either drug in Fontan patients and would have been difficult to acquire for nesiritide, given its identical structure to endogenously produced brain natriuretic peptide. It is possible that alternative dosing regimens or longer duration of administration of either study drug would produce different results. Catecholamines and NT-pro BNP were measured only in the first 47 patients, but the minimal differences in hormone levels among treatment groups in these patients suggest that these differences would not have been significant even in the full study cohort. We did not have informed parental consent or institutional review board approval to collect detailed information on the 90 eligible subjects who were not enrolled in the study and hence are unable to present any pre-Fontan assessment differences between these patients and trial participants. Finally, the study may have been underpowered to detect differences among treatment groups for the secondary outcomes.
Conclusions
Compared with placebo, empirical perioperative infusions of nesiritide or milrinone were not associated with improved early clinical outcomes after Fontan surgery. Patients treated with mirinone tended to be more likely to develop hypotension necessitating cessation of study drug and accelerated junctional rhythm. Neither drug can be recommended for routine use in children undergoing a primary Fontan operation. 
